PTIX — Protagenic Therapeutics Share Price
Last trade - 00:00- $1.20m
- $2.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
Directors
- Garo Armen CHM (68)
- Alexander Arrow CFO (51)
- Andrew Slee COO (71)
- Robert Stein DRC (70)
- Khalil Barrage IND (56)
- Jennifer Buell IND (46)
- Brian Corvese IND (63)
- Joshua Silverman IND (50)
- Last Annual
- March 31st, 2025
- Last Interim
- September 30th, 2025
- Incorporated
- February 3rd, 1994
- Public Since
- December 18th, 1996
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,934,878
- Address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, 10010
- Web
- https://protagenic.com/
- Phone
- +1 2129948200
- Auditors
- GreenGrowth CPAs
Upcoming Events for PTIX
Similar to PTIX
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 21:46 UTC, shares in Protagenic Therapeutics are trading at $0.62. This share price information is delayed by 15 minutes.
Shares in Protagenic Therapeutics last closed at $0.62 and the price had moved by -91.89% over the past 365 days. In terms of relative price strength the Protagenic Therapeutics share price has underperformed the S&P500 Index by -93.43% over the past year.
The overall consensus recommendation for Protagenic Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreProtagenic Therapeutics does not currently pay a dividend.
Protagenic Therapeutics does not currently pay a dividend.
Protagenic Therapeutics does not currently pay a dividend.
To buy shares in Protagenic Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.62, shares in Protagenic Therapeutics had a market capitalisation of $1.20m.
Here are the trading details for Protagenic Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PTIX
Based on an overall assessment of its quality, value and momentum Protagenic Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Protagenic Therapeutics is $4.00. That is 542.97% above the last closing price of $0.62.
Analysts covering Protagenic Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Protagenic Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -84.86%.
As of the last closing price of $0.62, shares in Protagenic Therapeutics were trading -79.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Protagenic Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Protagenic Therapeutics' management team is headed by:
- Garo Armen - CHM
- Alexander Arrow - CFO
- Andrew Slee - COO
- Robert Stein - DRC
- Khalil Barrage - IND
- Jennifer Buell - IND
- Brian Corvese - IND
- Joshua Silverman - IND